NASDAQ
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Open
$28.82
Previous Close
$28.51
Day High
$29.06
Day Low
$27.20
52 Week High
$47.65
52 Week Low
$9.69
No price data available for this timeframe.